Home/Pipeline/DrugSorb-ATR®

DrugSorb-ATR®

Removal of Ticagrelor/Rivaroxaban during cardio-pulmonary bypass surgery

Commercial (CE Mark) / Pivotal Trial (US)Marketed ex-US; Active Pivotal Trial (STAR-T) in US

Key Facts

Indication
Removal of Ticagrelor/Rivaroxaban during cardio-pulmonary bypass surgery
Phase
Commercial (CE Mark) / Pivotal Trial (US)
Status
Marketed ex-US; Active Pivotal Trial (STAR-T) in US
Company

About CytoSorbents

CytoSorbents is a commercial-stage medical device company with a mission to address life-threatening conditions through extracorporeal blood purification. Its core achievement is the CE-marked CytoSorb® device, which has seen significant adoption in over 75 countries for applications like cytokine storm in sepsis and intraoperative drug removal in cardiac surgery. The company's strategy hinges on expanding the clinical evidence base for its platform, pursuing U.S. regulatory approval for CytoSorb® and DrugSorb-ATR®, and leveraging its versatile technology into adjacent markets like veterinary medicine and organ perfusion. Success is contingent on converting its substantial international experience into FDA clearances to unlock the large U.S. critical care market.

View full company profile